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Transmembrane helixHuman phospholipid scramblase 1 (SCR) was originally described as an intrinsic membrane protein catalyzing
transbilayer phospholipid transfer in the absence of ATP. More recently, a role as a nuclear transcription factor
has been proposed for SCR, either in addition or alternatively to its capacity to facilitate phospholipid ﬂip-ﬂop.
Uncertainties exist as well from the structural point of view. A predicted α-helix (aa residues 288–306) located
near the C-terminus has been alternatively proposed as a transmembrane domain, or as a protein core structural
element. This paper explores the possibilities of the above helical segment as a transmembrane domain. To this
aim two peptideswere synthesized, one corresponding to the 19α-helical residues, and one containing both the
helix and the subsequent 12-residues constituting the C-end of the protein. The interaction of these peptides
with lipid monolayers and bilayers was tested with Langmuir balance surface pressure measurements,
proteoliposome reconstitution and analysis, differential scanning calorimetry, tests of bilayer permeability, and
ﬂuorescence confocal microscopy. Bilayers of 28 different lipid compositions were examined inwhich lipid elec-
tric charge, bilayer ﬂuidity and lateral heterogeneity (domain formation) were varied. All the results concur in
supporting the idea that the 288–306 peptide of SCR becomes membrane inserted in the presence of lipid bilay-
ers. Thus, the data are in agreement with the possibility of SCR as an integral membrane protein, without
rejecting alternative cell locations.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cellmembranes are composed of an asymmetric lipid bilayer inwhich
proteins are embedded. Some of these proteins, named ﬂippases and
ﬂoppases, are in charge of maintaining the transbilayer phospholipid
asymmetry [1,2], with PS predominantly in the inner leaﬂet. When cells
are challenged, in processes such as blood coagulation or apoptosis, intra-
cellular calcium increases accompanied by PS exposure to the outer leaﬂet
via an ATP-independent pathway [3]. The ﬁrst described member of the
phospholipid scramblase family, human phospholipid scramblase 1
(SCR) seems to be the main protein responsible for this event [4,5]. This
multifunctional protein is a type-2 membrane protein of 318 aa. It has
been described as a lipid raft-associated proteinwhenmultipalmitoylated
[6,7]. It has been predicted that SCR contains an N-terminus (1–287 aa)
cytoplasmic main portion, a putative transmembrane α-helix (288–onic acid sodium salt; DID, 1,1′-
PX, p-xylene-bis(pyridinium)
,1,3,3,3-hexaﬂuoro-2-propanol;
icles; PC, phosphatidylcholine;
l; PI, phosphatidylinositol; PS,
umanphospholipid scramblase
peptide; TM31C, SCR 288–318
ights reserved.306 aa), and a small C-terminus extracellular coil (307–318 aa) [8].
Protein-, lipid- and DNA-binding networks connected to SCR are abun-
dant, since posttranslational acylation acts as a switch controlling the
scramblase localization. In the absence of acylation, scramblase 1 is
imported into the nucleus where it binds DNA and acts as a transcription
factor [9,10].
The nature of the physiological activity of SCR in the cell remains
controversial. Its role as a scramblase has been challenged due to its
involvement in seemingly unrelated events in cell signaling [9,10].
Also relevant in this discussion is the recent identiﬁcation of
TMEM16F as the responsible protein for the defective phospholipid
scrambling in Scott syndrome when truncated [11]. The situation is
not better understood from the structural point of view. Sahu et al.
[12] found that the EF hand-like calcium-binding domains of the
scramblase family showed a marked deviation from the classical se-
quence, and suggested a novel class of low afﬁnity calcium-binding
domains. The scramblase anchoring to the membrane has also been
challenged [13] due to high similarities in the sequencewith the crystal-
lized homologous At5g01750 from Arabidopsis thaliana and also with
Tubby-like proteins, presuming that the highly hydrophobic α-helical
domain, sometimes considered as a transmembrane domain, might
remain buried in the protein core with the palmitoyl residues as the
only tether to the bilayer. However, in a recent paper, Francis et al.
[14] have provided evidence, based on ﬂuorescence quenching studies,
that the C-terminal α-helix inserts into membranes.
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two peptides were synthesized, one consisting of the putative trans-
membrane domain, TM19 [288KMKAVMIGACFLIDFMFFE306] and a sec-
ond one containing the TM domain plus the exoplasmic coil, TM31C
[288KMKAVMIGACFLIDFMFFESTGSQEQKSGVW318] (Fig. 1). No palmit-
oylation occurs in this part of the protein under physiological condi-
tions. Using a set of well-established biophysical approaches, we
studied the interactions of each peptide with model membranes of dif-
fering charges and/or phase structures. The results in this paper, togeth-
er with published topological predictions, give strong support to the
notion that the 288–306 peptide of SCR constitutes a transmembrane
domain rather than existing inside the protein core.2. Materials and methods
2.1. Chemicals
TM31C and TM19 were synthesized and purchased from PolyPep-
tide Group Laboratories (Strasbourg, France), and stored at −20 °C in
powder form. When required, they were dissolved in DMSO (Sigma)
or HFIP (Fluka). Egg phosphatidylcholine (PC), spinal cord phosphati-
dylserine (PS), egg phosphatidylethanolamine (PE), egg phosphati-
dylglycerol (PG) and liver phosphatidylinositol (PI) were purchased
from Lipid Products (Redhill, England). The remaining lipids were all
from Avanti Polar Lipids (Birmingham, AL, USA). 8-Aminonaphtalene-A
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Fig. 1. The structure of human SCR and of the putative transmembrane domain.
(A) Human SCRmain domains, the predicted transmembrane helix at the C-end ismarked
in red. (B) The two peptides used in this work, TM19, comprising the transmembrane do-
main, and TM31C,which includes the TM domain plus the extracellular coil. (C)Wheel di-
agram of TM19, hydrophobic residues are marked in red.1,3,6-trisulfonic acid sodium salt (ANTS), p-xylene-bis(pyridinium)
bromide (DPX) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indodi-
carbocyanine (DID) were obtained from Invitrogen (Life Technologies,
Carlsbad, CA, USA). The polyclonal anti-scramblase antibody was from
Oncogene (Cambridge, UK). FITC-linked anti-rabbit antibody was from
Abcam (Cambridge, UK) and HRP-linked anti-rabbit antibody was
from New England Biolabs (Ipswich, MA, USA). All other reagents
were of analytical grade. Assay buffer was 10 mM Hepes, 150 mM
NaCl, pH7.4.2.2. Langmuir balance measurements
Peptide-induced changes in surface pressure at the air–water inter-
face and peptide–lipid monolayer interactions were studied at 25 °C
using a 1.25mlmulti-well Delta Pi-4 Langmuir balance (Kibron Inc., Hel-
sinki, Finland). Monolayers were formed by spreading a small amount
of the lipid mixtures in chloroform:methanol (2:1, v/v) solution on
top of assay buffer until the desired initial surface pressurewas attained.
The peptides dissolved in DMSO (less than 0.5% of total volume) were
injected with a micropipette through a hole connected to the subphase,
and their surface activity followed bymeans of surface pressure changes
with constant stirring.2.3. Peptide binding quantiﬁcation
The appropriate amounts of peptide and LUVs were co-incubated at
a lipid-to-peptide ratio 75:1 for 2 h at 25 °C in a ThermoMixer
(Eppendorf, Hamburg, Germany). Sucrose gradient formation andultra-
centrifugation were carried out as in [15]. A fraction of this sample was
adjusted to a 1.4 M ﬁnal sucrose concentration (ﬁnal volume 300 μl),
overlaid with 400 μl 0.8M sucrose in buffer, and 300 μl 0.5 M sucrose.
The gradient was centrifuged at 400,000 ×g for 3 h, and then four
250 μl fractions were collected from the bottom of the tube with a
Hamilton syringe. The polycarbonate centrifuge tubes were then
washed with 250 μl hot 1% (w/v) SDS to recover the peptide that had
aggregated or adhered to the tube walls.
Dot blots were performed using a Hybond-C Extra (Amersham
Biosciences) membrane. The sucrose gradient-derived samples were
spotted onto the membrane and blocked with 5% skim milk for 1 h,
followed by 1h incubation with anti-scramblase antibody (1:400). The
blot was washed several times with PBS, pH7.4, and incubated for 1 h
with an HRP-linked anti-rabbit antibody (1:2000). After ﬁnal washings
to eliminate the unbound secondary antibody, the blot was developed
on a Curix 60 processor (AGFA, Belgium) using Amersham Hyperﬁlm
ECL (GE Healthcare, UK). The intensity of the sample signal was mea-
sured with a GS-800 densitometer (Bio-Rad, Stockholm, Sweden).2.4. Differential scanning calorimetry
All measurements were performed using a VP-DSC high-sensitivity
scanningmicrocalorimeter (Microcal, Northampton,MA, USA). For pep-
tide–MLVpreparation, the proper amounts of lipid in chloroform:meth-
anol (2:1, v/v) and peptide in HFIP were mixed and the solvents
evaporated exhaustively. The MLVs were then prepared by slowly hy-
drating the peptide-containing lipid ﬁlm with assay buffer at a temper-
ature above the lipid phase transition temperature, continuously
stirring with a glass rod and with vigorous vortexing. The samples
were then carefully degassed prior to the measurements. Assay buffer
was scanned as a background. The scan rate was 45 °C/h. Samples
were scanned several times to ensure the reproducibility of the endo-
therms. Data were analyzed using ORIGIN software provided by
MicroCal. Final volume and lipid concentration in the cell were 0.5 ml
and 0.5 mM respectively. Lipid concentration was measured as lipid
phosphorous using a molybdate reagent.
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Large unilamellar vesicles (LUVs)were prepared fromMLVs in assay
buffer in the presence of ANTS and DPX at a 1:3.6 ratio. The MLVs were
extruded 10 times through polycarbonate ﬁlters 0.1 μm in pore diame-
ter. The lipid suspension was then passed through a Sephadex PD-10
column to discard non-encapsulated dye. Vesicle content efﬂux or leak-
age was measured at 23–25°C in a FluoroMax luminescence spectrom-
eter following ANTS ﬂuorescence after peptide (dissolved in DMSO)
addition. ANTS was excited at 355 nm and emission was recovered at
520 nm using a cut-off ﬁlter at 475 nm. The initial vesicle suspension
was used to set the 0% ﬂuorescence signal while 100% ﬂuorescence
was obtained after vesicle lysis by 1mM Triton X-100 [16,17].
2.6. Solid-phase binding assay
A screening dot blot analysis was performed to assess the lipid afﬁn-
ities of TM31C [18]. Lipids were dissolved in methanol:chloroform:
water (2:1:0.8, v/v/v) at 800μM ﬁnal concentration and 1μl was spotted
on a Hybond-C Extramembrane and left for 1h to let the lipid dry. After
blocking with 0.75% skim milk in PBS for 1 h the membrane was incu-
bated for an additional hour with TM31C (500nM ﬁnal concentration)
also in PBS. The membrane was then washed several times, incubated
with antibodies and developed as detailed under Peptide binding
quantiﬁcation.
2.7. Peptide binding to electroformed GUVs and antibody tagging
Giant vesicleswere prepared using the electroformationmethod de-
veloped by Angelova et al. [19]. Stock lipid solutions (0.3mM total lipid
containing 0.5mol%DID)were prepared in a chloroform/methanol (2:1,
v/v) solution. 6μl of the lipid stocks were added onto the surface of two
platinum (Pt) electrodes located in a PRET-GUV 4 chamber supplied by
Industrias Técnicas ITC (Bilbao, Spain), and solvent traces removed by
placing the chamber under high vacuum for 1 h. The chamber was
then equilibrated at 55 °C for 15 min and the Pt electrodes covered
with 400 μl of a 300 mM sucrose solution, previously equilibrated at
55°C. The Pt electrodes were connected to a generator (TG330 function
generator, Thurlby Thandar Instruments, Huntingdon, UK) under AC
ﬁeld conditions (10 Hz, 0.9 V for 2 h, followed by 1 Hz, 0.9 V for
10 min) at 55 °C. Then, generator and water bath were switched off
and vesicles left to equilibrate for 30 min. The chamber (Lab-Tek™ II
chambered coverglass, Thermo Scientiﬁc) was previously incubated
with a 2mg/ml BSA solution for 30min to avoid vesicle rupture, and ex-
tensively washed thereafter with equiosmolar buffer solution.
Vesicles were then collected and 50 μl added to 250 μl of an
equiosmolar TM31C peptide solution (ﬁnal lipid:peptide ratio of 1:1;
ﬁnal peptide concentration of 0.66 μM) and placed into the chamber.
Sucrose-containing vesicles sedimented at the bottom of the chamber
due to their higher density, which facilitated vesicle stability and obser-
vation under the microscope. Incubation was left overnight at room
temperaturewithout stirring and in the darkness. Next, the vesicle solu-
tionswere carefullywashed4 timeswith equiosmolar assay buffer solu-
tion to remove non-bound peptide, always maintaining a ﬁnal volume
of 300μl. The vesicles were then incubatedwith the anti-scramblase an-
tibody (ratio 1:100) for 1 h under the same conditions. After several
washings to remove non-vesicle-bound antibody, a secondary, FITC-
linked anti-rabbit antibody (ratio 1:500) was added to the chamber
wells and incubated for an additional hour. The chamber was ﬁnally
washed several times to remove unbound secondary antibody.
2.8. Confocal microscopy
The chambered coverglass containing theGUVswas placed on top of
an inverted confocal ﬂuorescence microscope (Leica TCSSP5, Leica
Microsystems, Wetzlar, Germany). The excitation wavelengths forFITC (tagging the peptide) and DID (tagging the bilayers) were
488 nm and 633 nm respectively. Emission was recovered between
498–545 for FITC and 650–795 for DID. Both equatorial and 3D images
were obtained as required, and treated using the Leica Application
Suite software (LAS AF, Leica Microsystems).
2.9. Circular dichroism
CD spectra were recorded using a thermally controlled Jasco J-810
circular dichroism spectropolarimeter in a 0.1 cm quartz cell at room
temperature. The spectra were recorded from 190 nm to 250 nm, with
1 nm step resolution, 50 nm/min speed and 100mdeg sensitivity, data
being recorded every 0.2nm. The results of 40 scans were averaged.
Peptides were prepared in solution in 2mMHepes buffer, pH7.4, in
the presence or absence of 50% HFIP, or in membrane-mimicking
100 mM SDS micelles. Stock peptide samples dissolved in HFIP or
DMSO were lyophilized or desiccated overnight, and then rehydrated
at a 30 μM ﬁnal concentration. Spectra were buffer-corrected, and nor-
malized to mean residue ellipticity ([θ]) using the equation
θ½  ¼ εð Þ= 10  C  l  nð Þ
where θ is the molar ellipticity (degrees square centimeter per
decimole), ε is the ellipticity (millidegrees), C is the protein concentra-
tion (millimolar), l is the path length (centimeters), and n is the number
of peptide bonds.
3. Results
3.1. Langmuir balance measurements
The SCR sequence-derived transmembrane peptides should exhibit
a substantial afﬁnity towards lipid-based membranes. In order to test
this hypothesis, we initially performed peptide–lipid interaction studies
with the use of lipid monolayers in a Langmuir balance. First, the possi-
ble surface activity of TM19 and TM31C was assayed. Fig. S1A displays
representative time-courses of TM19-induced changes in surface pres-
sure at the air–buffer interface upon injection of increasing peptide con-
centrations into the subphase. The peptide induces a dose-dependent
increase in surface pressure. The TM domain plus the exoplasmic coil
(TM31C) shows a similar surface activity. Both TM19 and TM31C give
rise to peptide-basedmonomolecularﬁlms that are saturated at compa-
rable surface pressures (~22 mN/m at 3 μM peptide) (Fig. S1B). Thus,
both peptides display a tendency to get adsorbed to air–water inter-
faces, lowering their surface tension, i.e. they are both surface-active,
and both exhibit a similar surface activity.
We next tested the possible peptide–lipid interaction upon injection
of TM19 or TM31C into the subphase of a lipid–buffer interface. Specif-
ically, monolayers of either PC or a mixture of PC:PG at a 9:1mol ratio
were prepared at π0≥22mN/m, i.e. above the maximum surface pres-
sure of pure peptides at the air–buffer interface. Addition of 3 μM of ei-
ther TM19 or TM31C causes a clear increase in surface pressure (see
TM31C traces in Fig. S1C). This is interpreted in termsof the peptides be-
coming inserted into the lipid monolayers. By measuring the peptide-
induced maximum π increases at various initial surface pressures
(Fig. 2A), twomajor effects can be observed: i) TM31C presents a higher
afﬁnity than TM19 for the studied lipid monolayers and ii) both pep-
tides exhibit a stronger interaction in thepresence of 10mol%negatively
charged PG. Moreover, TM19 presents a critical surface pressure (πc or
maximum surface pressure beyondwhich no peptide insertion occurs),
of 27.5 mN/m for PC and 30mN/m for PC:PG 9:1 monolayers. TM31C
shows πc values of 33 and 37mN/m for PC and PC:PG monolayers re-
spectively. All πc values are of the order of magnitude of the estimated
30±5mN/m for cell membrane lateral pressure [20]. Hence, Langmuir
balance assays support a favorable interaction of both peptides, particu-
larly TM31C, with lipid monolayers.
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Fig. 2. Peptide interactionswith lipid monolayers and bilayers. (A) Insertion of TM31C and TM19 peptides into PC (●) and PC:PG 9:1 (Δ) lipidmonolayers. 3 μMpeptide was injected into
the subphase andmonolayerswere extended at different initial surface pressures π0. Equilibrium values of the peptide-induced surface pressure changes are shown. (B)Membrane bind-
ing assay of TMC31 peptide by sucrose gradient isolation. 1 to 4, samples recovered from top to bottom of the sucrose gradient. 5 corresponds to the material extracted with 1% SDS
from the tube wall. Recovered fractions of lipid (empty bars) and peptide (full bars) are shown. Average values± SEM (n= 3). Peptide:lipid mol ratios are indicated for each fraction.
(C, D) Representative DSC endotherms of pure DPPC (C) or pure pSM (D), and mixtures of those lipids with varying amounts of TM31C (represented as peptide:lipid ratios).
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Peptide interaction with model bilayers was ﬁrst assessed using a
ﬂotation assay, followed by dot blotting and immunodeveloping.
TM31C was used together with PC:PG 9:1 bilayers as they presented a
higher afﬁnity in monolayer studies. In this assay, after peptide:LUV
co-incubation, the sample is layered at the bottom of a sucrose gradient
and ultracentrifuged. Liposome-bound peptides ﬂoat on top of the gra-
dient, whereas the non-bound peptides sediment with the bottom
layer.
Fig. S1D displays the dot blot developed for this test and shows that
the pure peptide had to be extracted from the tubewall (“P”, sample 5).
However, the peptide incubated with LUVs remained partly in solution,
presumably incorporated into the vesicle membrane in the 4 layers re-
covered from the tube (“*”, samples 1 to 4). Fig. 2B shows the recovered
and quantiﬁed fractions of lipid and peptide when incubated together;
the peptide-to-lipid ratio (mol:mol) is indicated for each fraction.
From these results, it can be inferred thatwhen co-incubated, TM31C in-
teracts with PC:PG unilamellar vesicles (about ~60% of the peptide re-
mains bound to LUVs). The most visible band in the gradient is the top
one (fraction 1), containing the largest single fractions of both peptide
and lipid, at a≈1:70mol ratio. This is in accordance with the Langmuir
balance studies, however from the binding assays we cannot assess
whether the peptide is getting inserted into the bilayer or just adsorbed
on the bilayer.
3.3. The effect of TM19 and TM31C on DPPC and pSM bilayers
To further explore the interaction and organization of both peptides
in vesicles, we used differential scanning calorimetry (DSC). From the
protein or peptide effects on a gel–ﬂuid phase transition of a speciﬁc
lipid, the kind of interaction, insertion or adsorption, can be inferred
[21]. On this basis, we studied mixtures of each peptide with either
dipalmitoyl phosphatidylcholine (DPPC) or palmitoyl sphingomyelin
(pSM). DPPC and pSM show highly cooperative gel–ﬂuid phase-
transitions and are very suitable models for these assays.Fig. 2C shows the endothermic phase transitions for pure DPPC and
mixtures with TM31C. DPPC, as extensively reported, showed a pre-
transition at 34 °C and a main phase transition (Tm) centered at
41.3 °C (ΔT1/2 = 0.52 °C and ΔH = 44.6 KJ/mol). Both TM31C and
TM19 in the range investigated (from 1:500 to 1:10 peptide:lipid
ratio) cause the disappearance of the pre-transition, a clear broadening
of the main phase transition and a decrease of the associated enthalpy,
while the transition temperature is largely maintained. The abolition
of the pre-transition and the decreased enthalpy of the main DPPC
phase transition without major changes in Tm are generally associated
with insertion processes [21]. Fig. S2B and C show the thermodynamic
parameters obtained from the thermograms of DPPC with TM31C and
TM19. Both peptides show a similar insertion behavior.
Moreover, interactions of each peptide with palmitoyl sphingomyelin
(pSM) bilayers were tested. SM lacks a pre-transition but presents a clear
gel–ﬂuid phase transition at similar temperatures as DPPC. Fig. 2D shows
the endothermic phase transitions for pure pSMandbinarymixtureswith
TM31C peptide. Pure pSM multilamellar vesicles show a main phase
transition centered at 41.1 °C (ΔT1/2= 0.99 °C and ΔH=30.9 KJ/mol).
In this case peptide addition in the range investigated (from 1:500 to
1:25 peptide:lipid ratio) also caused a signiﬁcant broadening and loss
of the phase transition-related enthalpy as compared to the pure
sphingolipid. Fig. S2E and F show the changes on pSM enthalpy and
transition width as a function of peptide:pSM ratio for each peptide.
In general, the calorimetric data is in good agreement with monolayer
studies, showing that both peptides become inserted in phospholipid
bilayers.3.4. Bilayer permeability and solid-phase binding measurements
A series of vesicle content leakage experiments were performed
with the aim of studying peptide-induced perturbations in membrane
permeability. The following bilayers were used: i) pure POPC in a
liquid-disordered (ld) phase state, ii and iii) egg PC in the presence of
10 mol% negatively-charged PG or PI, iv) PC containing 10 mol%
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domains, PC:PE:Chol 2:1:1 and vi) PC:oleic acid at a 9:1 ratio.
Fig. 3A shows representative time-courses of TM31C-induced re-
lease of ANTS–DPX contents (detected as an increase in ANTS ﬂuores-
cence upon release from the vesicles) for POPC, PC:PG and PC:PE:Chol.
The extent of vesicle efﬂux is clearly dependent on lipid composition
suggesting that peptide insertion is equally sensitive to the lipidmixture
in the bilayers.
The steady-state data for the release of ANTS–DPX are shown in
Fig. 3B–G for various peptide concentrations. PC:PG (B) induces the
maximum observed leakage in the presence of TM31C (around 22%,
after ~2 h at Ri 0.02). A lower but still signiﬁcant content efﬂux is ob-
served in the presence of any charged lipid, or of oleic acid. Content
leakage in the presence of TM31C decreased in the order: PC:PG
9:1 N PC:ethylPC 9:1 N PC:PI 9:1 ≈ PC:oleic acid 9:1 N PC:PE:Chol
2:1:1N POPC.
TM19 induces a clearly smaller ANTS leakage than TM31C with all
tested compositions, probably due to its hydrophobic character and
subsequent instability in aqueous solution. Only with PG- andTime (s)
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Fig. 3. (A) Representative time-courses of TM31C-induced release of intravesicular aque-
ous contents for a number of lipid membrane compositions, as indicated for each curve.
(B–G) Release of vesicle contents induced by TM19 (○) and TM31C (●) at 25°C, as a func-
tion of peptide:lipid mol ratio. The composition of lipid vesicles (LUV) is (B) PC:PG 9:1,
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Average values± SEM (n=3). Lines are used to guide the eye.ethylPC-containing vesicles do we observe any substantial content out-
ﬂow. In general, under any conditions tested, none of our samples be-
have as the typical lytic peptides, e.g., δ-lysin, or equinatoxin [22–25].
The rates of efﬂux for the different bilayer compositions could pro-
vide some idea of the respective afﬁnities for the peptide. Fig. 4A
shows that TM31C causes faster efﬂux in bilayers containing charged
lipids, either PI, ethylPC or PG. Both zwitterionic bilayers show substan-
tially lower rates. The higher efﬂux from vesicles containing charged
lipids can be attributed to the presence of both negatively- and
positively-charged residues in the peptides (Fig. 1). Oleic acid-
containing bilayers show an intermediate leakage rate. Thismight be re-
lated to a fatty-acid induced decrease inmembrane lateral order, thus, a
more favorable peptide interaction. A solid-phase binding assay for
TM31C and the previous lipid compositions is shown in Fig. 4B. No dif-
ferences are observed among the assayed mixtures, except for a some-
what lower binding for POPC. Thus, differential binding does not
appear to be the main cause for the observed differences in content re-
lease and efﬂux rate probably reﬂecting a further event beyond binding,
i.e. insertion.
3.5. The effect of lipid phase
In order to test the effect of lipid phase and phase segregation on
peptide–membrane interactions, we examined TM19- and TM31C-
induced vesicle content release in POPC:pSM:Cholmixtures at 22 differ-
ent ratios selected from the detailed phase diagram by de Almeida and
collaborators [26] (Fig. 5A). Fig. 5B shows TM31C-induced representa-
tive time-course leakage traces for 7 chosenmixtures at the different re-
gimes. Interestingly, we observe that the mixtures showing higher
efﬂux levels are those presenting a solid-ordered phase (so) in coexis-
tence with a ld, a lo or both phases. Among these mixtures, the onePC
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of the vesicles, either made of a pure lipid phase or with phase coexis-
tence in the absence of a so phase, causes a lesser membrane perturba-
tion. Vesicles made of pure so phase do not present any measurable
leakage. In the case of TM19, total release on any of the 22mixtures test-
edwas less than 3% (data not shown), thus, TM19data are not discussed
any further. From this analysis we conclude that phase segregation
could have a direct impact in TM31C-induced vesicle content release.
The observed differences between the studied mixtures support an in-
creased peptide–membrane afﬁnity in the presence of certain phase
boundaries, the lo–so being the most effective.
Efﬂux results for the 22 mixtures described in Fig. 5A are presented
in full in Fig. 6. Fig. 6A summarizes the extent of TM31C-induced leakage
under apparent equilibrium conditions at a 1:50 peptide-to-lipid ratio
for the 22 analyzed vesicle compositions. The presence of a so phase in
the membrane enhances ANTS leakage. This can be clearly noticed in
the POPC:pSM:Chol compositions 1:7:2 and 2:7:1 (lo + so) or 1:1:0
(ld+so). The boundaries between the so and the other phases are unsta-
ble regions in themembrane, containing structural defects. We propose
a more favorable TM31C insertion into the membrane via these bound-
aries.We can as well notice a larger efﬂux at 1:7:2 (lo+so) vesicle com-
position in comparison with the 1:1:0 (ld + so) vesicles. This could
reﬂect a higher instability of the lo+so boundaries or a preferential af-
ﬁnity of TM31C towards cholesterol-containing interfaces and/or
phases.
In Fig. 6B–C, the behavior of TM31C on eleven lipid mixtures among
those allowing the highest leakages, is examined in more detail. Fig. 6Breveals an interesting inﬂuence of cholesterol on the release rate. The
two fastest processes examined occur in mixtures containing 30–50%
Chol (mixtures #15, 16),while the slowest releases are found in compo-
sitions containing 0–10% Chol (mixtures #8, 9, 19).
Fig. 6C summarizes the results of lipid solid-phase binding assays for
the mixtures studied in Fig. 6B. We observe a strong TM31C-binding to
0:1:1 composition (#15) followed by 1:6:3 (#16) composition. POPC:
pSM:Chol 1:7:2 composition (#18) that showed high leakage shows
also high binding. The presence of cholesterol in themembrane, that en-
hances leakage rate, also increases the peptide solid-phase binding.
Table 1 summarizes the results obtained from experiments
displayed on Fig. 6. There is no strict correlation between peptide bind-
ing to bilayers, and rate and extent of content release. However, the
combined data appear to indicate that the coexistence of so and other
phases facilitates the extent of leakage, while cholesterol appears to
enhance peptide binding to the membranes, and increase release rates.
The question on whether all mixtures tested would release their
aqueous contents through the same mechanism, graded or all-or-none
[27],was examinednext. The procedure is based on the fact that the life-
times of calcein ﬂuorescence are concentration-dependent. Analysis of
time-resolved ﬂuorescence decay permits the simultaneous observa-
tion of different calcein populations. A graded release, as a function of
peptide:lipid ratio, should lead to a gradual, peptide-concentration de-
pendent, change in calcein lifetime. Several mixtures were tested but,
Table 1
Membrane binding of TM31C peptide to vesicles (LUV) of different lipid compositions and
subsequent permeabilization. Measurements as shown in Figs. 5 and 6. The number in
parentheses after the lipid composition refers to the phase diagram in Fig. 5A. Data are
average values± SEM (n=3).
POPC:pSM:Chol Leakage (%) Efﬂux rate (s−1) Binding (c.u.)
1:0:0 (#1) 4.1± 1.03 0.056± 0.003 1.1± 0.44
95:0:5 (#2) 4.1± 1.14 0.068± 0.003 1.2± 0.32
85:15:0 (#3) 1.4± 0.57
7:0:3 (#4) 2.4± 0.31
7:1:2 (#5) 3.1± 0.42 0.153± 0.049 2.1± 0.25
2:1:1 (#6) 1.4± 0.90 0.033± 0.010 1.9± 0.08
1:1:1 (#7) 1.9± 0.07
1:1:0 (#8) 19.6± 3.49 0.038± 0.012 2.1± 0.37
4:5:1 (#9) 7.9± 2.83 0.005± 0.002 2.3± 0.34
3:5:2 (#10) 1.8± 0.15
2:2:1 (#11) 3.1± 0.29
4:0:6 (#12) 0.5± 0.27
3:1:6 (#13) 1.3± 0.60
1:4:5 (#14) 2.5± 0.10
0:1:1 (#15) 4.6± 0.57 0.286± 0.065 4.4± 0.73
1:6:3 (#16) 7.9± 2.25 0.359± 0.117 3.4± 0.58
2:6:2 (#17) 5.8± 1.62 0.156± 0.032 2.8± 0.56
1:7:2 (#18) 35.5± 5.10 0.077± 0.028 2.9± 0.63
2:7:1 (#19) 28.8± 4.04 0.015± 0.004 1.9± 0.26
0:8:2 (#20) 3.0± 0.57 0.157± 0.030 2.8± 0.56
15:85:0 (#21) 2.4± 0.17
0:1:0 (#22) 1.6± 0.20 0.051± 0.007 2.6± 0.52
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very different degrees of leakage, an all-or-none mechanism is clearly
observed in all cases, with invariant calcein lifetimes irrespective to
peptide–lipid ratios. The all-or-none mechanism also speaks in favor
of the efﬂux being the results of an irreversible insertion, rather than re-
versible adsorption.IgG FITC
PC
PC:PG
9:1
POPC:pSM:Chol
1:7:2
Fig. 7. Imaging of TM31C binding to GUVs. Confocal microscopy of GUVs (equatorial sections) el
incubatedwith vesicles overnight and subsequently incubatedwith anti-scramblase antibody (
488 goat anti-rabbit IgG (1:500) for an additional hour. Peptide (green) and lipid (red) staining a
is displayed at the right-hand column.3.6. TM31C location in GUVs
Peptide binding to giant unilamellar vesicles was directly assessed
by confocal microscopy. With this aim, vesicles and TM31C were co-
incubated and later the peptide tagged with an anti-scramblase C-
terminal antibody and a FITC-containing secondary antibody. The con-
focal micrographs displayed in Fig. 7 correspond to equatorial sections
of GUVs electroformed and labeled with the lipophilic probe DID.
Speciﬁcally, we addressed TM31C interaction with pure PC, PC:PG
(9:1mol ratio) and POPC:pSM:Chol 1:7:2 (mol ratio). Phase separation
in the latter mixture (#18) is clearly seen in the picture, the solid region
exhibiting a smaller radius of curvature. Confocal microscopy shows a
negligible peptide interaction with pure zwitterionic PC giant vesicles,
according to the leakage assay and the solid-phase binding (Figs. 3
and 4). However, direct peptide labeling can be observed in PG-
containing vesicles and in the ﬂuid domains of those exhibiting phase
separation, as in POPC:pSM:Chol 1:7:2 (mixture #18). The combination
of leakage and confocal microscopy would support TM31C insertion
into the bilayers and its preferential afﬁnity for negatively-charged
and domain-containing bilayers.
3.7. Peptide helicity
The helicity of TM19 and TM31C in solution and in a membrane-
mimetic environment was examined using circular dichroism. The re-
sults displayed in Fig. S5 show that both TM31C (A–C) and TM19 (B–
D) in buffer are unstructured. But upon addition of 50% HFIP or in the
presence of membrane-mimicking SDSmicelles, TM31C adopts a main-
ly helical conformation, exhibiting two minima near 208 and 222 nm,
characteristic of α-helical conformation. In contrast, TM19 assumes a
β structure in both tested cases with a minimum located between 210
and 220 nm, which may indicate TM19 self-association adopting aDiD Merge
ectro-formed from differentmixtures of lipids containing 0.5% (mol:mol) DID. Peptidewas
1:100) for 1h. Anti-scramblase antibodywas detected by incubating themixturewith FITC
re shown at the left-hand and center columns; themerging of theDID and the FITC images
395I.M.D. Posada et al. / Biochimica et Biophysica Acta 1838 (2014) 388–397β-sheet organization. The molar ellipticity of both peptides in HFIP is
substantially higher compared to the ellipticity obtained in a micellar
environment. The higher propensity of TM31C to form an α-helix may
be related to the higher afﬁnity of TM31C for bilayers, as compared to
that of TM19, observed in a variety of experiments.
4. Discussion
The results on this paper show that the predicted transmembrane
peptide of human SCR is surface active and can insert into lipid mono-
layers and bilayers in a way that is dependent on the lipid nature and
properties. These observations will now be brieﬂy discussed, and put
in the context of our current knowledge of SCR.
4.1. The surface properties of TM19 and TM31C peptides
Both peptides under study display surface properties that are poten-
tially interesting in understanding the structure and function of SCR.
Speciﬁcally:
(i) The peptides are surface active. Both TM31C and TM19 partition
at an air–water interface (Fig. S1A–B), demonstrating the
surface-active nature of these scramblase regions [28]. An in-
crease in surface pressure in the range of 0.1–1.0mN/m per resi-
due is to be expected for amphipathic amino acid stretches [29].
In ourmeasurements, the corrected pressure per residue is above
0.77 for both peptides, an indication that almost all the peptide
residues are adsorbed to the interface.
(ii) The peptides bind lipid monolayers and bilayers. Both peptides
are able to insert into lipid monolayers above the pure peptide-
limiting pressure of 22mN/m as seen in Fig. 2A. The critical pres-
sures or πc were calculated for each peptide by linear ﬁtting of
the experimental Δπ vs. π0 values and were in both cases of the
order of magnitude of the presumed physiological lateral pres-
sure of cell membranes, about 30 mN/m [20]. πc values were
higher for the long peptide, probably due to its stability in solu-
tion, and in the presence of the negatively charged lipid PG.
These results indicate that scramblase transmembrane domain
peptides possess the capacity to interact with monolayers and,
as suggested by the πc values, to insert into bilayers [28,30].
This is in agreement with the recent results by Francis et al.
[14]. Moreover, liposomes containing bound peptide are recov-
ered from the top fraction of sucrose gradients after centrifuga-
tion (Fig. 2B).
Further evidence for peptide insertion into lipid bilayers arises
from DSC. The thermograms obtained for DPPC or pSM in the
presence of peptides (Fig. 2C–D and S2A–D) demonstrate their
insertion capacity.When a peptide or a protein becomes inserted
into a bilayer, the cooperativity of the lipid phase is decreased
[21], broadening the transition and lowering the associated en-
thalpy, as found for cholesterol [31,32]. However, when the pep-
tide or the protein is just adsorbed to the bilayer, lipid
cooperativity is not lost and the transition temperature is often
increased [33]. The scramblase predicted transmembrane pep-
tides follow the insertion model, with ΔH signiﬁcantly lowered
and the transition peak broadened in all tested cases (Fig. 2C–D
and S2). Note that the effects of TM19 and of TM31C on the
lipid phase transitions are virtually identical, supporting the no-
tion that the 19-aa stretch reﬂects a transmembrane domain.
The gel–ﬂuid transition of SM appears to be somewhat more re-
sponsive to peptide insertion than that of DPPC.
An additional approach to the assessment of peptide–lipid bind-
ing is provided by solid-phase binding (Fig. S3, 4B and 6C) [18].
Although this technique does not allow a very precise quantita-
tion, it is useful as a ﬁrst approximation when a large number
of lipids/lipid mixtures have to be tested, as in our case.Moreover, confocal microscopy (Fig. 7) supplies direct evidence
of peptide binding to bilayers. Thus, a large variety of techniques
and results concurs in demonstrating the membrane afﬁnity of
TM19 and TM31C.
(iii) The peptides break the solubility barrier of lipid bilayers. Beyond
themere binding, the peptides cause profound changes in mem-
brane architecture, leading to its permeabilization and subse-
quent leakage of vesicle aqueous contents (Figs. 3–6 and
Table 1). Peptides of multiple origins can permeabilize the lipid
bilayer [22–24,34–37]. In our study, in virtually all cases mem-
brane binding was followed by content efﬂux. These results are
discussed in detail below, in the present context they just under-
line the membranotropic character of our peptides.4.2. Bilayer permeabilization by TM19 and TM31C
LUV formed from a variety of lipid mixtures was initially tested
(Figs. 3 and 4). Peptide binding did not differ greatly with lipid compo-
sition (Fig. 4B). Themain conclusionswere that (i) TM19wasmuch less
effective than TM31C in causing content release, and (ii) electrically
charged bilayers, either positively or negatively, supported more exten-
sive and faster release than their zwitterionic counterparts. The low af-
ﬁnity of TM19 in this context is interesting, because the DSC results
(Fig. 2 and S2) show that both peptides insert equally well in bilayers.
However, for DSC studies lipids and peptides are mixed in organic sol-
vent before bilayer formation, while for content release the peptides
are added in a small volume of DMSO to preformed vesicles. The highly
hydrophobic nature of TM19 is probably causing its aggregation before
it can reach the vesicles, become inserted and cause release, i.e. TM19
activity at the membrane level may be much lower than its total
concentration.
The efﬂux-enhancing role of electric charges in the bilayer is also no-
ticeable (Figs. 3 and 4A), particularly in combination with their lack of
effect on membrane binding (Fig. 4B). This probably reﬂects that bind-
ing occurs essentially through hydrophobic interactions, while perme-
abilization requires the additional concurrence of electrostatic factors.
Note that the N- and C-terms of TM19 are charged amino acids, respec-
tively positive (Lys) and negative (Glu). TM31C contains further
charged residues that may also help in leakage induction.
4.3. The inﬂuence of lipid phases
In zwitterionic bilayers, the presence of saturated and unsaturated
phospholipids, and of cholesterol, in different proportions, gives rise to
a variety of situations in which different pure phases occur, and often
coexist in the same sample, giving rise to domains. A well-studied sys-
tem of that kind is represented by the POPC, pSM and Chol triangular
phase diagram built by de Almeida et al. [26]. A number ofmixtures dis-
tributed along the phase diagramwere selected for our leakage experi-
ments summarized in Figs. 5 and 6, and Table 1. A similar strategy had
been followed by Pokorny et al. [22] to study lipid interactions with δ-
lysin, a bacterial hemolytic peptide.
Some generalizations can be made in view of the results in Figs. 5
and 6, and Table 1: (i) the extent of leakage is very low for mixtures
consisting of pure gel (so) phase, e.g., #21 and 22, or for pure lo phase,
e.g., #12 and 13; the opposite is true for mixtures in which the so
phase coexists with ld, e.g., #3, or with lo, e.g., #18 and 19. (ii) There is
no strict correlation between mixtures allowing a large extent of efﬂux
and those permitting fast efﬂux. The fastest rates are found for compo-
sitions #15 and 16, rich in pSM and Chol, that supported an intermedi-
ate amount of leakage.Mixture #9, in which a coexistence of ld, lo and so
phases occurs, is a slow releaser, but the total efﬂux is substantial. (iii)
The rate of release of vesicular contents is somewhat related to lipid–
peptide binding, see e.g., mixtures #15, 16 and 20. (iv) In all cases test-
ed, content release appears to follow an all-or-none mechanism.
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sive leakage had been done even in pure lipid systems, in the absence
of peptides [38–40]. Moreover, some protein toxins have been found
that become inserted at the gel–ﬂuid interfaces in bilayers [37]. Pokorny
et al. [22] did not observe this interfacial effect, but they did not explore
in detail the region of solid–ﬂuid coexistence in the phase diagram. In
any case, it should be noted that our peptides, even the most active
one TM31C, never achieved above 40% release in our hands, much less
than δ-lysin that can induce efﬂux of 80% dye under certain conditions.
This is interpreted in terms of the very different presumed functions of
TM31C (protein anchor to the membrane) and δ-lysin (defense pep-
tide). In a recent paper Spaller et al. [41] observe that most peptides
that cause all-or-none release are not hemolytic, and the opposite is
due of peptides causing gradient release of vesicular contents (note,
however, that the hemolytic protein α-hemolysin from Escherichia coli
did cause all-or-none release of liposomal contents [42]).
4.4. The 288–306 peptide as a transmembrane domain
The main object of this work was to elucidate whether or not the
288–306 peptide of SCR could be a transmembrane domain, hence to
test the possibility of SCR as a membrane protein under physiological
conditions. The experiments described above provide multiple indica-
tions that the 288–306 peptide becomes inserted in lipid bilayers in
themanner of integral proteins. The experimental data are also support-
ed by theoretical predictions. According to the Wimley–White octanol
hydrophobicity scale [43] the peptide scores negative in free energy
(ΔG=−1.01±0.13), so it is predicted to be transmembrane. In these
calculations, intramembrane Asp residue was considered to be electri-
cally neutral [44]. The same result is obtained when the “translocon bi-
ological hydrophobicity scale” [45] is used. Moreover α-helical
segments buried inside proteins are signiﬁcantly less hydrophobic
than this one, and the hydrophobic amino acids are not all in one contin-
uous sequence as in our case (Fig. 1) [46].
These predictions cannot be taken by themselves as certainties, but
the combination of predictive and experimental work provides a very
strong evidence that the 288–306 peptide SCR is indeed membrane-
inserted, thus, that the protein, even in the absence of acylation, can
be membrane-anchored, as required for the phospholipid transbilayer
transport activity.
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